ISSN: 2578-501X
Authors: Anubha Bajaj*
An infrequent (≤1.2%), aggressive B lymphocyte non hodgkin’s lymphoma is designated as a Burkitt’s lymphoma, which may present as an extra-nodal tumefaction or as an acute leukaemia [1]. A well delineated clinico-pathological disorder, Burkitt’s lymphoma elucidates minimal morphological, phenotypic and molecular diversity. The proliferating tumour displays a rapid doubling time of approximately twenty five hours. The clinical sub-categories of the Burkitt’s lymphoma may be: i) endemic Burkitt’s lymphoma (e BL) ii) sporadic Burkitt’s lymphoma (s BL) and iii) immune deficiency related Burkitt’s lymphoma (id BL) [1]. A frequent, paediatric class of Burkitt’s lymphoma (4-12 years) with an extra-nodal representation of the jaw or assorted facial bones(50-60%), is the ENDEMIC variant with an identical geographic apportionment as the Plasmodium falciparum. The primary tumour may disseminate to the mesentery, ovary, testis, breast and meninges. Limited to the African children, the endemic variant may account for roughly half (30-50%) of the childhood malignancies. An estimated 3-6 patients /100000 population per year may be detected
Keywords: Lymphoma; Chemotherapy; Antiretroviral Therapy
